Double immunotherapy attack after Chemo-Radiation shows promise for lung cancer

NCT ID NCT03285321

Completed Disease control Sponsor: Greg Durm, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) after standard chemoradiation could better control stage III lung cancer compared to nivolumab alone. 105 patients were randomly assigned to one of the two treatment groups. The main goal was to see how long patients lived without their cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (Opdivo) and ipilimumab (Yervoy)
What this could lead to: If successful, this could offer a more effective way to keep stage III lung cancer from progressing after standard chemoradiation, potentially extending the time before the disease worsens.
What could go wrong: This is a relatively small Phase 2 trial, so results may not be definitive. Combining two immunotherapy drugs can increase the risk of serious immune-related side effects, and the benefit over standard care is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Indiana University

Indianapolis, Indiana, 46202, United States
Johns Hopkins Sidney Kimmel Comprehensive

Baltimore, Maryland, 21287, United States
Karmanos Cancer Center (Wayne State University)

Detroit, Michigan, 48201, United States
Michigan State University

Lansing, Michigan, 48910, United States
Penn State Cancer Institute

Hershey, Pennsylvania, 17033, United States
Rush University Medical Center

Chicago, Illinois, 60612, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
University of Illinois Cancer Center

Chicago, Illinois, 60612, United States
University of Louisville James Graham Brown Cancer Center

Louisville, Kentucky, 40202, United States
University of Minnesota

Minneapolis, Minnesota, 55455, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
University of Wisconsin

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.